Evidence map›Paper›PMID 37114505›Full record

ArticleThe Journal of international medical research2023

Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma.

Jiani Nie, Lianhe Li, Fuxian Tan, Hongmei Wang, Hongmin Wang, Liangyu Zou, Zhenlei Wen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Hsa_circ_0101308 adjusted by N6-methyladenosine (mCancer biomarkers : section A of Disease markers · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiani NieChengde Medical University, Heibei, China.ORCID 0000-0002-6810-9737
Lianhe LiDepartment of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Chaoyang, Liaoning, China.
Fuxian TanDepartment of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Chaoyang, Liaoning, China.
Hongmei WangDepartment of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Chaoyang, Liaoning, China.
Hongmin WangDepartment of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Chaoyang, Liaoning, China.
Liangyu ZouDepartment of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Chaoyang, Liaoning, China.
Zhenlei WenDepartment of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Chaoyang, Liaoning, China.
Chengde Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the relationship between CADM1 expression and sensitivity to TPF-induced chemotherapy in laryngeal squamous cell carcinoma (LSCC) patients, then investigate its potential mechanisms.

methodsDifferential CADM1 expression was examined in chemotherapy-sensitive and chemotherapy-insensitive LSCC patient samples after TPF-induced chemotherapy using microarray analysis. Receiver operating characteristic (ROC) curve analysis and bioinformatics approaches were used to investigate the diagnostic value of CADM1. Small interfering RNAs (siRNAs) were used to knock down CADM1 expression in an LSCC cell line. Differential CADM1 expression was compared by qRT-PCR assays in 35 LSCC patients treated with chemotherapy, including 20 chemotherapy-sensitive and 15 chemotherapy-insensitive patients.

resultsPublic database and primary patient data both suggest that CADM1 mRNA is expressed at lower levels in chemotherapy-insensitive LSCC samples, suggesting its potential usefulness as a biomarker. Knockdown of CADM1 with siRNAs led to decreased sensitivity of LSCC cells to TPF chemotherapy.

conclusionsUpregulation of CADM1 expression can alter the sensitivity of LSCC tumors to TPF induction chemotherapy. CADM1 is a possible molecular marker and therapeutic target for induction chemotherapy in LSCC patients.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsLaryngeal NeoplasmsMicroRNAsCell Adhesion Molecule-1Cell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMicroarray AnalysisRNA, Small InterferingSquamous Cell Carcinoma of Head and NeckCADM1 protein, humanCell Adhesion Molecule-1MicroRNAsRNA, Small InterferingbiomarkerCADM1chemosensitivityinduction chemotherapyLaryngeal squamous cell carcinomaTPF

Identifiers

PMID37114505
PMCPMC10331191
OpenAlexW4367315736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.